Blood transfusions at end of life for stem cell transplant patients.

Authors

null

Winnie S Wang

UC San Diego Internal Medicine Residency Program, San Diego, CA

Winnie S Wang, Joseph D. Ma, Sandahl H Nelson, Carolyn Revta, Gary T Buckholz, Carolyn M. Mulroney, Eric Roeland

Organizations

UC San Diego Internal Medicine Residency Program, San Diego, CA, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, University of California San Diego Moores Cancer Center, La Jolla, CA, University of California San Diego, La Jolla, CA

Research Funding

Other

Background: Transfusions are an essential palliative tool in the stem cell transplant (SCT) population. Limited data exist regarding transfusion practices at end-of-life for SCT patients and whether these practices may limit enrollment in hospice. Methods: A retrospective chart review was conducted of deceased patients with hematologic malignancies who underwent SCT at an academic medical center from 2011 to 2015. The primary objective was to determine the difference between the dates of last transfusion and death in patients enrolled and not enrolled in hospice. A secondary objective was evaluation of the number of transfusions between groups. Data were compiled from a single electronic medical record. Descriptive analyses were performed. Days to last transfusion were analyzed using the Wilcoxon-Mann-Whitney test. Number of packed red blood cell (PRBC) transfusions and platelets transfusions on the last day were analyzed using Fisher and chi-squared tests, respectively. Results: A total of 633 SCT were performed from 2011 to 2015 including 39% (n = 245) allogeneic and 61% (n = 388) autologous transplants (n = 29 patients had 2 transplants). Mean ± SD age of SCT patients was 55 ± 13 years. As of January 2016, 20% (n = 119) of these SCT patients have died. Of those that died, 15% (n = 18) were enrolled in hospice. For SCT patients enrolled in hospice, the mean ± SD time of last blood transfusion from death was 42.3 ± 63.4 days, with mean ± SD 0.67 ± 0.77 units of PRBC’s and 0.72 ± 0.75 units of platelets administered. For SCT patients not enrolled in hospice, the mean ± SD time of last blood transfusion from death was 14.2 ± 47.9 days, with mean±SD total 0.69 ± 1.03 units of PRBC’s and 1.14 ± 1 units of platelets administered. Hospice patients had a statistically significant longer number of days until last blood transfusion compared to non-hospice patients (p < 0.001). There was no difference between SCT patients enrolled in hospice and not enrolled in PRBC transfusions (p = 0.069), but there was a significantly higher amount of platelet transfusions in patients not enrolled in hospice (p < 0.005). Conclusions: This data suggests that time to last transfusion may be a significant obstacle for SCT patients when enrolling in hospice, but requires further validation.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 Palliative and Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Evaluation and Assessment of Patient Symptoms and Quality of Life,Integration and Delivery of Palliative Care in Cancer Care

Sub Track

Barriers to care across systems

Citation

J Clin Oncol 34, 2016 (suppl 26S; abstr 115)

DOI

10.1200/jco.2016.34.26_suppl.115

Abstract #

115

Poster Bd #

E5

Abstract Disclosures

Similar Abstracts

First Author: Carley Mitchell

First Author: Melissa R Rosen

Abstract

2021 ASCO Quality Care Symposium

Serious illness conversation and end of life care utilization at an academic medical center.

First Author: William P. Tompkins